ibrutinib CAS NO.936563-96-1

Anqing World Chemical Co.,Ltd.Mainly responsible for the development of domestic and international business.In 2015,Haikang established the second branch,called Anqing Xuanyu Medical&Technology Co., Ltd, it is an R&D company that selects reliable technology and cooperative research partner for our corporation.

Haikang is committed to R&D,manufacture and sales of chemical raw materials API and intermediates.Meanwhile,we also provide services like product customization,process improvement,achievement transfer, etc. Through years effort,Haikang has made remarkable achievements in the R&D and production of anti-virus,antidiabetic,antineoplastic,beauty and whitening resist oxidation series API and intermediates.The main products are Ganciclovir, Sitagliptin, Vildagliptin, Silodosin and Imatinib API and Intermediates.

To deal with increasingly competition,Haikang adheres to “Customer is First,Technology is Leading,Quality is Life,Honesty for Developing”,and optimizes actively the products and better service to customers.

Haikang is looking forward to heading for win-win cooperation and a brilliant future with you!

Ibrutinib (Ibrutinib) was first developed by Celera Genomics (Celera Genomics), which is famous for mapping the human genome. In 2007, it was developed by Pan Zhengying (now Peking University Shenzhen). Graduate School Distinguished Researcher) published the process of developing ibrutinib as the first author (ChemMedChem2(1):58-61), but due to Celera funding and resource issues, Celera transferred the drug development rights to California in 2006 Pharmacyclics. Although Pharmacyclics was in a very difficult stage at the time, the stock was only $0.64 at the lowest, and it was facing delisting and bankruptcy. However, the chemicalbook management layer of the company managed to raise funds and only spent a down payment of $2 million, plus 1 million shares and the future. Ibrutinib was awarded to the sales commission and the equity paid by the milestone. In 2011, Jassen, a subsidiary of Johnson & Johnson, obtained the right to cooperate with Pharmacyclics through an initial payment of US$150 million. Once the new drug is successfully clinically tested and approved for listing, Pharmacyclics Pharmaceuticals will receive a total of US$975 million in revenue. It will also share the sales proceeds. When the deal was announced, Pharmacyclics stock was only $12, with a market value of only a few hundred million dollars. So far, its stock is 123 US dollars, and the market value is 9.05 billion US dollars.

Ibrutinib is an inhibitor of BTK kinase. It can covalently bind to the cysteine residues in the active center of BTK, thereby inhibiting the activity of B cells. It has a significant effect on B-cell lymphoma, especially Chemicalbook for those who are difficult to relapse. A variety of patients with advanced lymphoma. Among them, there is evidence to support: chronic lymphocytic leukemia/small lymphocytic leukemia CLL/SLL, mantle cell lymphoma MCL